Finally, although most of the evidence of a potential benefit of GLP-1 RAs in HF originates from CVOTs in type 2 diabetes, it may likely be in the weight management setting that the drug class could be of the highest clinical value, particularly in people with HFpEF
DOI: Published online: February 13, 2026 1 Department of Internal Medicine, MedStar Washington Hospital Center, Washington, DC, USA 2 Georgetown University Medical Center, School of Medicine, Georgetown University, Washington, DC, USA 3 Department of Medicine, School of Medicine, Georgetown University, Washington, DC, USA 4 Department of Internal Medicine, School of Medicine, University of Jordan, Amman, Jordan 5 Department of Gastroenterology and Hepatology, INOVA Medical System, Leesburg, VA, USA Correspondence: Ahmad Abdulraheem Department of Internal Medicine, MedStar Washington Hospital Center, 110 Irving St NW, Washington, DC 20010 USA E-mail: [email protected] 2026 Korean Society of Gastrointestinal Endoscopy This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
Es Seguro Ribupatide
"It is important to understand how these drugs actually work
Embark on a journey towards better health and a brighter future
In published metabolic and longevity research, 5-Amino-1MQ is often referenced alongside other compounds investigated for energy-expenditure, NAD+ and methyl-pool research
